Abraxane as adjuvant misses primary in resected pancreatic cancer

Celgene said Abraxane nab-paclitaxel plus gemcitabine missed the primary endpoint of improving disease-free survival vs. gemcitabine alone in the Phase III apact trial evaluating the drugs as adjuvant therapy for patients with surgically resected pancreatic adenocarcinoma.

The open-label, international trial enrolled 866 patients. ...